Quick Answer
Coherus Oncology, Inc. reported Diluted EPS of $1.43 per share for fiscal year 2025.
Coherus Oncology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.43 | +472.0% |
| 2024 | $0.25 | +109.9% |
| 2023 | -$2.53 | +32.7% |
| 2022 | -$3.76 | +1.3% |
| 2021 | -$3.81 | -335.2% |
| 2020 | $1.62 | +31.7% |
| 2019 | $1.23 | +138.2% |
| 2018 | -$3.22 | +28.1% |
| 2017 | -$4.48 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | -244.4% | -112.1% |
| June 30, 2025 | $2.57 | +2436.4% | +624.5% |
| March 31, 2025 | -$0.49 | -153.8% | -444.4% |
| September 30, 2024 | -$0.09 | +78.0% | +18.2% |
| June 30, 2024 | -$0.11 | +77.6% | -112.1% |
| March 31, 2024 | $0.91 | +194.8% | +322.0% |
| September 30, 2023 | -$0.41 | +63.1% | +16.3% |
| June 30, 2023 | -$0.49 | +24.6% | +49.0% |
- Coherus Oncology, Inc. showed an increase of +472.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, Coherus Oncology, Inc.’s diluted eps has grown by 131.9% (from $4.48 per share (loss) to $1.43 per share).
- The most recent figure is from Coherus Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: